ClinicalTrials.gg
Active, not recruitingNCT01589302Updated Apr 13, 2026Results posted

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

A Phase 2 interventional study of ibrutinib and Correlative laboratory samples in Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia, sponsored by Kami Maddocks, MD. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Kami Maddocks, MD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 144 studies in Leukemia, Prolymphocytic with a site in United States — 5 open to participants now, 11 under way, none of them phase 3. Leukemia, Prolymphocytic · United States.

Enrollment
13th of 115
154 · median 35
Started
2012
with 5 others
Phase 2
47 of 144
3 open now
Primary completion
2016-07
later than 1 of 10 live
Registered
120th of 144
by date

Among the 144 studies in Leukemia, Prolymphocytic with a site in United States, this one is the 13th largest by enrollment of the 115 interventional ones that give a count, is one of 6 that started in 2012, is one of 47 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 120th registered.

Leukemia, Prolymphocytic

172 studies on the registry are indexed under Leukemia, Prolymphocytic; 5 are open to participants now.

Browse Leukemia, Prolymphocytic studies →

Open to participants now

5 of the 144 studies in Leukemia, Prolymphocytic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Leukemia, Prolymphocytic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Leukemia, Prolymphocytic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II, single institution open-label, non-randomized monotherapy study to evaluate the clinical efficacy and durable disease control of PCI-32765 administered to patients with relapsed/refractory CLL/SLL/PLL of all risk categories with patients having deletion 17p13 independently evaluated.

Read the detailed description

This is a clinical trial, a type of research study, involving treatment with an investigational (experimental) drug called PCI-32765 (Ibrutinib), a "kinase inhibitor". "Kinases" are proteins that are inside of cells and help them to live and grow. The specific kinase inhibited or blocked by this study drug is believed to help blood cancer cells grow and live. By inhibiting or "blocking" the activity of this kinase, it is possible that the study drug may be able to kill the cancer cells or stop them from growing. This study will involve treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL) that has not responded to or has relapsed after standard treatment. This trial is studying how effective PCI-32765 is at treating CLL, SLL, or B-PLL and all the effects, good and/or bad, treatment with this drug has on patients and their cancers.

03

Conditions studied

  • Prolymphocytic Leukemia
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory/Relapsed Chronic Lymphocytic Leukemia

Keywords

  • Bruton's Tyrosine Kinase
  • CLL
  • SLL
  • B-PLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CLL/SLL who require treatment and have failed at least one prior therapy.
  • Patients must have available results of interphase cytogenetics CLL fluorescent in situ hybridization (FISH) panel; the cytogenetic analysis must be done prior to starting therapy but after any recent therapy
  • (ECOG) performance status =\< 2
  • greater than 2 months
  • =\< 1.5 X the institutional unless due to Gilbert's disease or disease related to (AST) or alanine aminotransferase (ALT) =\< 2.5 X the institutional upper limit of normal unless disease related
  • Creatinine =\< 1.5 X the institutional upper limit of normal unless disease related
  • (ANC) >= 0.75 X 10\^9/L
  • count >= 30 X 10\^9/L
  • Agree to use during the study and for 30 days after the last dose of study drug if sexually active and able to bear children
  • Ability to understand and the willingness to sign a written document
  • Patients with uncontrolled or active infection requiring antibiotic therapy; patients with controlled infections who are receiving extended antibiotics or prophylactic therapy are not excluded

Exclusion criteria

Exclusion Criteria:

  • Patients who have had chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to the first dose of study drug ( for disease-related symptoms allowed but doses equivalent to > 20 mg prednisone orally per day require 1 week before study drug administration or steroid dose must be equal to =\< 20 mg prednisone orally daily)
  • Patients who have not recovered from adverse events of >= grade 3 toxicity due to agents administered more than 4 weeks ago
  • Receiving any other agents
  • Previously randomized to any PCI-32765 clinical trial
  • Known secondary that limits survival to less than two years
  • Patients with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  • Patients requiring anti-coagulation with warfarin or other Vitamin K antagonists or heparin products including low molecular weight heparin (LMWH)
  • Currently active, hepatic impairment class B or C according to the Child Pugh classification
  • Patients requiring treatment with a strong cytochrome P450 3A4/5 (/5) and/or cytochrome P450 2D6 (CYP2D6) inhibitor
  • Patients with a life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification
  • Active central nervous system (CNS) involvement by lymphoma
  • Pregnant or women who are breastfeeding
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Treatment (ibrutinib)

    Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.

    Drug: ibrutinib · Other: Correlative laboratory samples · Other: quality of life assessment

Interventions

  • Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Also known as: Bruton's tyrosine kinase inhibitor PCI-32765, BTK inhibitor PCI-32765, PCI-32765

  • OtherCorrelative laboratory samples

    Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.

    Also known as: laboratory biomarker anyalysis

  • Otherquality of life assessment

    During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.

06

What researchers measure

Primary outcomes

  1. Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL.

    We will summarize our findings for this endpoint independently as well within each cohort (del17p vs other cytogenetic groups). We will evaluate the proportion of patients who are progression-free and alive at two years or have gone on to transplant (treatment successes) over the total number of evaluable patients; eligible patients who received at least one dose of therapy are considered evaluable. Assuming that the number of treatment successes as defined above is binomially distributed, we will also include 95% binomial confidence intervals for the estimates corresponding to each cohort.

    Time frame: up to 2 years

Secondary outcomes

  1. Best Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines

    Responders were subjects who achieved a complete response (CR), partial response (PR) or PR with persistent lymphocytosis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: up to 2 years

  2. Number of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients

    The 6 month overall response rates overall response rate (ORR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Up to 6 months

  3. Percentage of Patients With Overall Survival (OS)

    Time from date of first treatment with ibrutinib until the date of death from any cause or the date of last contact for those alive.

    Time frame: 2 years

  4. 2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765

    Time from date of first treatment with ibrutinib until the date of progression or death from any cause. Those alive and progression free are censored at the date of last clinical assessment.

    Time frame: 2 years

  5. Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

    Adverse events grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 with the attribution of either definite, possible or probable related.

    Time frame: Up to 2 years post treatment

  6. Resistance Studies of Ibrutinib

    Percentage of patients with BTK C481S mutation or PLCG2 mutation

    Time frame: Up to 4 years

  7. Decrease in Immune Suppression of CLL Cells

    Time frame: up to 3 months

  8. Effectiveness of Ibrutinib Bridging Patients to Allogeneic Stem Cell Transplant and Outcome of Patients Following This Intervention

    The number of participants with successful Allogenic Stem Cell Transplant

    Time frame: Up to 2 years

  9. Cancer-Specific Stress as Measured by the Impact of Event Scale-Revised (IES-R)

    Cancer-Specific Stress was measured by the Impact of Event Scale-Revised Participants rated the intensity of these feelings using a five-point Likert scale ranging from 0=not at all to 4=extremely. Patients rated the frequency of their feelings or events for the previous week before treatment. The items were summed for a total score that ranged from 0 to 64

    Time frame: Up to 2 years

  10. Cognitive-Affective Depressive Symptoms as Measured by the Beck Depression Inventory-2nd Edition (BDI-II)

    The Beck Depression Inventory-2nd edition is a 21-item measure of depressive symptoms. Scores were calculated representing the cognitive-affective and the somatic symptoms associated with depression (e.g. sadness, pessimism, loss of pleasure) during past month on scale from 0 to 3. Items were summed, with higher scores indicating more depressive symptoms. The scores on the scale from range from 0 to 42.

    Time frame: at 5 months

  11. Negative Mood Quality of Life Measured by a 37-item Questionnaire

    The Profile of Mood States-Short Form (POMS-SF) yields six subscales, Tension, Depression, Anger, Vigor, Fatigue, and Confusion. A total mood disturbance score is found by summing the six subscales. Total Mood Disturbance (TMD) scores range from -24 to 124 with higher scores indicating greater mood disturbance.

    Time frame: at 5 months

  12. Mental Health Quality of Life Was Measured by the Mental Component Summary Score of the Medical Outcomes Study

    SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning.

    Time frame: at 5 months

  13. Fatigue Symptom Inventory (FSI) Interference Quality of Life as Measured by a 11-item Total Disruption Index Sub Scale of Fatigue Symptoms Inventory

    The Fatigue Interference quality of life measures is a 11-item self reported questionnaire used to measure frequency, severity and daily pattern of fatigue Symptoms as well as impact of QOL in the past week. The Total Disruption Index (TDI) an 7 item subset of FSI was used. Items were rated on a 11-point Likert scale from 0=no interference to 10=extreme interference. Total scores could range from 0 to 70, with higher scores indicating greater fatigue interference.

    Time frame: at 5 months

  14. Sleep Through Quality of Life as Measured by a Medical Outcomes Study-Sleep Scale

    Sleep problems quality of life measures is a six-item sleep problems index I of the Medical Outcomes Study-Sleep Scale used to assess sleep problems. Participants reported how often they experience six specific difficulties with sleep on a 6-point Likert scale (1=All of the time to 6=None of the time). Scores transformed into a 0-100 scale with higher scores indicating greater sleep problems.

    Time frame: at 5 months

  15. Physical Health Quality of Life as Measured by a 12 Item Short-Form Health Survey

    Physical Health Quality of life measures were administered during screening and on Days 1 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru Cycle 24 and at time of progression and /or end of treatment. SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning.

    Time frame: up to 5 months

07

Results

Posted May 21, 2019

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Ibrutinib)
Started154
Del17p patients76
Non-del17p patients76
Completed152
Not completed2

Outcome measures

PrimaryDetermine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL.

We will summarize our findings for this endpoint independently as well within each cohort (del17p vs other cytogenetic groups). We will evaluate the proportion of patients who are progression-free and alive at two years or have gone on to transplant (treatment successes) over the total number of evaluable patients; eligible patients who received at least one dose of therapy are considered evaluable. Assuming that the number of treatment successes as defined above is binomially distributed, we will also include 95% binomial confidence intervals for the estimates corresponding to each cohort.

Time frame:
up to 2 years
Reported as:
Number · percentage of patients
Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL.
percentage of patientsTreatment (Ibrutinib)
All patients64 (57 to 72)
Del(17p)64 (54 to 75)
non-Del(17p)64 (54 to 75)
SecondaryBest Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines

Responders were subjects who achieved a complete response (CR), partial response (PR) or PR with persistent lymphocytosis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
up to 2 years
Reported as:
Number · percentage of patients
Best Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines
percentage of patientsTreatment (Ibrutinib)
All patients63 (55 to 70)
Del(17p)66 (55 to 76)
non-Del(17p)59 (48 to 70)
SecondaryNumber of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients

The 6 month overall response rates overall response rate (ORR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Up to 6 months
Reported as:
Number · patients
Number of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients
patientsTreatment (Ibrutinib)
All patients63 (55 to 70)
Del(17p)66 (55 to 76)
Non-del(17p)59 (48 to 70)
SecondaryPercentage of Patients With Overall Survival (OS)

Time from date of first treatment with ibrutinib until the date of death from any cause or the date of last contact for those alive.

Time frame:
2 years
Reported as:
Number · percent of patients
Percentage of Patients With Overall Survival (OS)
percent of patientsTreatment (Ibrutinib)
All patients78 (71 to 84)
Del(17p)75 (63 to 83)
non-Del(17p)81 (71 to 89)
Secondary2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765

Time from date of first treatment with ibrutinib until the date of progression or death from any cause. Those alive and progression free are censored at the date of last clinical assessment.

Time frame:
2 years
Reported as:
Number · percent of patients
2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765
percent of patientsTreatment (Ibrutinib)
All patients69 (61 to 76)
Del(17p)66 (54 to 76)
non-Del(17p)72 (60 to 81)
SecondaryNumber of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Adverse events grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 with the attribution of either definite, possible or probable related.

Time frame:
Up to 2 years post treatment
Reported as:
Number · patients
Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
patientsTreatment (Ibrutinib)
Anemia13
Febrible Neutropenia2
Leukocytosis18
Atrial Fibrillation1
Diarrhea2
Gastric Hemorrhage1
Gastrointestinal Disorders-other1
Mucositis Oral1
Nausea2
Death1
Edema Limb1
Fatigue1
General Disorders and Admin Site Conditions2
Cholecystitis1
Bronchial Infection1
Infections and Infestations-other4
Lung Infection10
Otitis Media1
Sepsis2
Skin Infection2
Urinary Tract Infection1
Alanine Aminotransferase Increased1
Blood Bilirubin Increased1
Lymphocyte Count Decreased14
Lymphocyte Count Increased54
Neutrophil Count Decreased40
Platelet Count Decreased8
White Blood Cell Decreased10
Hyperuricemia4
Hypophosphatemia1
Arthralgia2
Arthritis1
Hematuria2
Hypoxia1
Respiratory Failure1
Rash Maculo-papular1
Hematoma1
Hypertension7
SecondaryResistance Studies of Ibrutinib

Percentage of patients with BTK C481S mutation or PLCG2 mutation

Time frame:
Up to 4 years
Reported as:
Number · percentage of patients
Resistance Studies of Ibrutinib
percentage of patientsTreatment (Ibrutinib)
Resistance Studies of Ibrutinib13.2 (8.2 to 19.6)
SecondaryDecrease in Immune Suppression of CLL Cells
Time frame:
up to 3 months

No measurements were reported for this outcome.

SecondaryEffectiveness of Ibrutinib Bridging Patients to Allogeneic Stem Cell Transplant and Outcome of Patients Following This Intervention

The number of participants with successful Allogenic Stem Cell Transplant

Time frame:
Up to 2 years
Reported as:
Number · participants
Effectiveness of Ibrutinib Bridging Patients to Allogeneic Stem Cell Transplant and Outcome of Patients Following This Intervention
participantsTreatment (Ibrutinib)
Effectiveness of Ibrutinib Bridging Patients to Allogeneic Stem Cell Transplant and Outcome of Patients Following This Intervention1
SecondaryCancer-Specific Stress as Measured by the Impact of Event Scale-Revised (IES-R)

Cancer-Specific Stress was measured by the Impact of Event Scale-Revised Participants rated the intensity of these feelings using a five-point Likert scale ranging from 0=not at all to 4=extremely. Patients rated the frequency of their feelings or events for the previous week before treatment. The items were summed for a total score that ranged from 0 to 64

Time frame:
Up to 2 years
Reported as:
Mean · units on a scale
Cancer-Specific Stress as Measured by the Impact of Event Scale-Revised (IES-R)
units on a scaleTreatment (Ibrutinib)
Cancer-Specific Stress as Measured by the Impact of Event Scale-Revised (IES-R)9.18 ± 8.35
SecondaryCognitive-Affective Depressive Symptoms as Measured by the Beck Depression Inventory-2nd Edition (BDI-II)

The Beck Depression Inventory-2nd edition is a 21-item measure of depressive symptoms. Scores were calculated representing the cognitive-affective and the somatic symptoms associated with depression (e.g. sadness, pessimism, loss of pleasure) during past month on scale from 0 to 3. Items were summed, with higher scores indicating more depressive symptoms. The scores on the scale from range from 0 to 42.

Time frame:
at 5 months
Reported as:
Mean · units on a scale
Cognitive-Affective Depressive Symptoms as Measured by the Beck Depression Inventory-2nd Edition (BDI-II)
units on a scaleTreatment (Ibrutinib)
Cognitive-Affective Depressive Symptoms as Measured by the Beck Depression Inventory-2nd Edition (BDI-II)1.88 ± 3.11
SecondaryNegative Mood Quality of Life Measured by a 37-item Questionnaire

The Profile of Mood States-Short Form (POMS-SF) yields six subscales, Tension, Depression, Anger, Vigor, Fatigue, and Confusion. A total mood disturbance score is found by summing the six subscales. Total Mood Disturbance (TMD) scores range from -24 to 124 with higher scores indicating greater mood disturbance.

Time frame:
at 5 months
Reported as:
Mean · units on a scale
Negative Mood Quality of Life Measured by a 37-item Questionnaire
units on a scaleTreatment (Ibrutinib)
Negative Mood Quality of Life Measured by a 37-item Questionnaire0.89 ± 18.12
SecondaryMental Health Quality of Life Was Measured by the Mental Component Summary Score of the Medical Outcomes Study

SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning.

Time frame:
at 5 months
Reported as:
Mean · units on a scale
Mental Health Quality of Life Was Measured by the Mental Component Summary Score of the Medical Outcomes Study
units on a scaleTreatment (Ibrutinib)
Mental Health Quality of Life Was Measured by the Mental Component Summary Score of the Medical Outcomes Study53.98 ± 8.72
SecondaryFatigue Symptom Inventory (FSI) Interference Quality of Life as Measured by a 11-item Total Disruption Index Sub Scale of Fatigue Symptoms Inventory

The Fatigue Interference quality of life measures is a 11-item self reported questionnaire used to measure frequency, severity and daily pattern of fatigue Symptoms as well as impact of QOL in the past week. The Total Disruption Index (TDI) an 7 item subset of FSI was used. Items were rated on a 11-point Likert scale from 0=no interference to 10=extreme interference. Total scores could range from 0 to 70, with higher scores indicating greater fatigue interference.

Time frame:
at 5 months
Reported as:
Mean · units on a scale
Fatigue Symptom Inventory (FSI) Interference Quality of Life as Measured by a 11-item Total Disruption Index Sub Scale of Fatigue Symptoms Inventory
units on a scaleTreatment (Ibrutinib)
Fatigue Symptom Inventory (FSI) Interference Quality of Life as Measured by a 11-item Total Disruption Index Sub Scale of Fatigue Symptoms Inventory9.70 ± 13.11
SecondarySleep Through Quality of Life as Measured by a Medical Outcomes Study-Sleep Scale

Sleep problems quality of life measures is a six-item sleep problems index I of the Medical Outcomes Study-Sleep Scale used to assess sleep problems. Participants reported how often they experience six specific difficulties with sleep on a 6-point Likert scale (1=All of the time to 6=None of the time). Scores transformed into a 0-100 scale with higher scores indicating greater sleep problems.

Time frame:
at 5 months
Reported as:
Mean · units on a scale
Sleep Through Quality of Life as Measured by a Medical Outcomes Study-Sleep Scale
units on a scaleTreatment (Ibrutinib)
Sleep Through Quality of Life as Measured by a Medical Outcomes Study-Sleep Scale24.08 ± 17.23
SecondaryPhysical Health Quality of Life as Measured by a 12 Item Short-Form Health Survey

Physical Health Quality of life measures were administered during screening and on Days 1 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru Cycle 24 and at time of progression and /or end of treatment. SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning.

Time frame:
up to 5 months
Reported as:
Mean · units on a scale
Physical Health Quality of Life as Measured by a 12 Item Short-Form Health Survey
units on a scaleTreatment (Ibrutinib)
Physical Health Quality of Life as Measured by a 12 Item Short-Form Health Survey44.23 ± 11.31

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Ibrutinib)—152/152 (100%)152/152 (100%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventTreatment (Ibrutinib)
Lung InfectionInfections and infestations32/152
Infections and Infestations-otherInfections and infestations13/152
SepsisInfections and infestations6/152
Febrile NeutropeniaBlood and lymphatic system disorders5/152
Death NOSGeneral disorders and administration site conditions5/152
Upper Respiratory InfectionInfections and infestations5/152
FeverGeneral disorders and administration site conditions4/152
Bronchial InfectionInfections and infestations4/152
Skin InfectionInfections and infestations4/152
Metabolism and Nutrition Disorders - OtherMetabolism and nutrition disorders4/152
Most frequent other events
Showing 10 of 80
Most frequent other events
EventTreatment (Ibrutinib)
Musculoskeletal and Connective tissue disorder-otherMusculoskeletal and connective tissue disorders104/152
DiarrheaGastrointestinal disorders100/152
FatigueGeneral disorders83/152
Neutrophil count decreasedInvestigations80/152
Gastrointestional DisorderGastrointestinal disorders73/152
Upper Respiratory InfectionInfections and infestations72/152
MucositisGastrointestinal disorders70/152
BruisingInjury, poisoning and procedural complications70/152
Lymphocyte count increasedInvestigations70/152
Weight gainInvestigations65/152

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment (Ibrutinib)
Del17p patients66 (42 to 91)
Non-Del17p patients64 (26 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Ibrutinib)
Female44
Male108
Region of Enrollment
Region of Enrollment(patients)Treatment (Ibrutinib)
United States152
08

Study locations

1 site
09

References and documents

Publications

  • Arrato NA, Valentine TR, Byrd JC, Jones JA, Maddocks KJ, Woyach JA, Andersen BL. Illness representations and psychological outcomes in chronic lymphocytic leukaemia. Br J Health Psychol. 2022 May;27(2):553-570. doi: 10.1111/bjhp.12562. Epub 2021 Oct 4. PubMed 34608724 ↗
  • Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17. PubMed 28714866 ↗
  • Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. PubMed 26182309 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Jul 2016, 50 months.

Results were first posted in May 2019, 2 years 9 months after primary completion.

Of 20 phase 2 interventional studies under Leukemia, Prolymphocytic, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 64 and three quarters within 159. This study's 50 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2012
First posted
May 1, 2012
StartActual
May 21, 2012
Primary completionActual
Jul 28, 2016
CompletionEst.
Oct 31, 2026
Results first posted
May 21, 2019
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01589302
Lead sponsor
Kami Maddocks, MD
Responsible party
Kami Maddocks, MD (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
May 1, 2012
Start date
May 21, 2012
Primary completion
Jul 28, 2016
Completion
Oct 31, 2026 (estimated)
Results posted
May 21, 2019
Last update
Apr 13, 2026

Study contacts

Kami Maddocks, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion